These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27617404)

  • 61. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1.
    Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR
    Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.
    Rutkowski JL; Wu K; Gutmann DH; Boyer PJ; Legius E
    Hum Mol Genet; 2000 Apr; 9(7):1059-66. PubMed ID: 10767330
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular, genetic, and cellular pathogenesis of neurofibromas and surgical implications.
    Gottfried ON; Viskochil DH; Fults DW; Couldwell WT
    Neurosurgery; 2006 Jan; 58(1):1-16; discussion 1-16. PubMed ID: 16385324
    [TBL] [Abstract][Full Text] [Related]  

  • 64. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Secretome survey of human plexiform neurofibroma derived Schwann Cells reveals a secreted form of the RARRES1 protein.
    Chen HL; Seol H; Brown KJ; Gordish-Dressman H; Hill A; Gallo V; Packer R; Hathout Y
    Int J Mol Sci; 2012; 13(7):9380-9399. PubMed ID: 22942771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PTEN and NF1 inactivation in Schwann cells produces a severe phenotype in the peripheral nervous system that promotes the development and malignant progression of peripheral nerve sheath tumors.
    Keng VW; Rahrmann EP; Watson AL; Tschida BR; Moertel CL; Jessen WJ; Rizvi TA; Collins MH; Ratner N; Largaespada DA
    Cancer Res; 2012 Jul; 72(13):3405-13. PubMed ID: 22700876
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influence of hormones and hormone metabolites on the growth of Schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin.
    Roth TM; Ramamurthy P; Muir D; Wallace MR; Zhu Y; Chang L; Barald KF
    Dev Dyn; 2008 Feb; 237(2):513-24. PubMed ID: 18213578
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.
    Beert E; Brems H; Daniëls B; De Wever I; Van Calenbergh F; Schoenaers J; Debiec-Rychter M; Gevaert O; De Raedt T; Van Den Bruel A; de Ravel T; Cichowski K; Kluwe L; Mautner V; Sciot R; Legius E
    Genes Chromosomes Cancer; 2011 Dec; 50(12):1021-32. PubMed ID: 21987445
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.
    Wu M; Wallace MR; Muir D
    J Neurosci Res; 2005 Nov; 82(3):357-67. PubMed ID: 16180234
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vascular wall cells contribute to tumourigenesis in cutaneous neurofibromas of patients with neurofibromatosis type 1. A comparative histological, ultrastructural and immunohistochemical study.
    Friedrich RE; Holstein AF; Middendorff R; Davidoff MS
    Anticancer Res; 2012 May; 32(5):2139-58. PubMed ID: 22593502
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.
    Kobayashi D; Hirayama M; Komohara Y; Mizuguchi S; Wilson Morifuji M; Ihn H; Takeya M; Kuramochi A; Araki N
    J Biol Chem; 2014 Sep; 289(38):26314-26326. PubMed ID: 25092287
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plexiform neurofibromas in NF1: toward biologic-based therapy.
    Packer RJ; Gutmann DH; Rubenstein A; Viskochil D; Zimmerman RA; Vezina G; Small J; Korf B
    Neurology; 2002 May; 58(10):1461-70. PubMed ID: 12041525
    [TBL] [Abstract][Full Text] [Related]  

  • 73. KIR2DL5 mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth.
    Anastasaki C; Dahiya S; Gutmann DH
    Oncotarget; 2017 Jul; 8(29):47574-47585. PubMed ID: 28548933
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas.
    Serra E; Rosenbaum T; Nadal M; Winner U; Ars E; Estivill X; Lázaro C
    Nat Genet; 2001 Jul; 28(3):294-6. PubMed ID: 11431704
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations.
    Carroll SL; Stonecypher MS
    J Neuropathol Exp Neurol; 2004 Nov; 63(11):1115-23. PubMed ID: 15581179
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Subclassification of nerve sheath tumors by gene expression profiling.
    Holtkamp N; Reuss DE; Atallah I; Kuban RJ; Hartmann C; Mautner VF; Frahm S; Friedrich RE; Algermissen B; Pham VA; Prietz S; Rosenbaum T; Estevez-Schwarz L; von Deimling A
    Brain Pathol; 2004 Jul; 14(3):258-64. PubMed ID: 15446580
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
    Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
    Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cellular Origin, Tumor Progression, and Pathogenic Mechanisms of Cutaneous Neurofibromas Revealed by Mice with
    Radomska KJ; Coulpier F; Gresset A; Schmitt A; Debbiche A; Lemoine S; Wolkenstein P; Vallat JM; Charnay P; Topilko P
    Cancer Discov; 2019 Jan; 9(1):130-147. PubMed ID: 30348676
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tissue culture methods to study neurological disorders: establishment of immortalized Schwann cells from murine disease models.
    Watabe K; Sakamoto T; Kawazoe Y; Michikawa M; Miyamoto K; Yamamura T; Saya H; Araki N
    Neuropathology; 2003 Mar; 23(1):68-78. PubMed ID: 12722929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.